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Who are they? Our intestinal system harbors an enormous number of non-pathogenic bacteria, eukaryotic microorganisms, archaea, viruses and bacteriophages, comprising a community collectively referred to as the intestinal microbiota. Bacteria account for the majority of these microorganisms: their total number in the human gut is estimated at 10 14 cells, which roughly equals the number of human cells in our body. Over 500 different bacterial species build a dynamic community consisting of both persistent and transient members. The microbial community structure is influenced by genotype, immune status, age, diet and environmental factors, and consequently varies among different people. Also, changes in nutrient availability and oxygen concentration along the gastrointestinal tract are reflected in regional differences in bacterial concentrations and community composition.
Our relationship with the entire intestinal microbiota can be described as symbiotic, with both partners benefiting. At present, however, direct evidence for the beneficial nature of only a few species within the community exists. Thus, many bacterial species may be classified as commensals, as they benefit from the nutrient-rich environment in the intestine yet their presence has no beneficial consequence to the host. The intestinal microbiota also harbors opportunistic pathogens, which have the potential to cause disease if the human host defenses are compromised.
Where do they come from? How do we tolerate them? As long as we are healthy, the intestinal immune response to bacteria or bacterial products has two principal outcomes: tolerance to the microbiota and response to pathogenic bacteria. There are many contributing factors allowing the immune system to distinguish between pathogenic and non-pathogenic bacterial stimuli to ensure the proper response. The most significant distinguishing feature is the ability of pathogenic bacteria to invade spaces that are usually devoid of bacteria, such as epithelial crypts, the epithelial surface, epithelial cells and the lamina propria.
Tolerance to the intestinal microbiota is thus maintained partially by ignorance of the host to bacterial products in the lumen. In addition, the microbiota actively places constraints on the host immune system by downregulating inflammatory immune responses. Maintaining a fine balance between immune tolerance and response is extremely important, as hypersensitive responses to the microbiota have been implicated as the cause of inflammatory bowel disorders such as Crohn's disease and ulcerative colitis.
What if they turn against us?
We normally coexist peacefully with our microbiota. However, any factor disturbing the intestinal ecosystem has the potential to lead to disease. For example antibiotic treatment, infection, surgery, chemotherapy or other medical procedures or diseases that weaken the immune system may cause the escape of opportunistic pathogens from the intestinal lumen, resulting in systemic infection. While the net metabolic activity of the microbial community in a healthy host appears to be health-promoting, individual metabolic products may be toxic and have been connected to gastrointestinal cancers. Epidemiological studies have linked an altered composition of the intestinal microbiota with the development of atopic eczema, arthritis and allergic diseases.
How can we support them?
Many factors such as our diet, diseases and drug treatments can disturb the intestinal microbiota composition and thus cause disease or intestinal discomfort. To alleviate the symptoms of conditions linked to an altered microbiota, treatments are being developed with the general goal of increasing the number of beneficial bacteria at the cost of those bacteria having neutral or detrimental effects. The major approaches are: prebiotics, which are dietary supplements that are preferably metabolized by health-promoting bacteria; probiotics, which are based on direct administration of beneficial bacteria; or synbiotics, which is a combination of these.
What else do we need to learn about them? Because our intestinal microbiota is incredibly diverse and dynamic, and we each host a unique community of bacteria, it is problematic to interpret epidemiological data and thus to determine the cause-effect relationship of diseases and an altered microbiota. Additionally, most intestinal bacteria are strictly anaerobic and/or are not culturable in the laboratory, making it difficult or even impossible to access them experimentally. To overcome these constraints, gnotobioticsthe study of germ-free or exgerm-free animals that have been colonized with a defined microbiota usually consisting of one or a few bacterial specieshave been used to elucidate many molecular and physiological aspects of beneficial hostbacteria interactions.
However, questions concerning bacteria-bacteria interactions within the intestinal microbial community cannot be addressed using these techniques, and it is most likely that the impact of a community consisting of more than 500 diverse members is different from that of a single bacterial species. An alternative approach is to use cultureindependent molecular methods, such as sequencing bacterial 16S rRNA genes, to define the microbial community. However, molecular information does not necessarily relate to bacterial physiology. Thus combining existing methods and developing new methods are necessary to address the many complex questions that remain to be answered concerning our microbial gut community.
